RE:RE:RE:RE:RE:RE:RE:BLA and FDA Fast Track Question?The key to revenues from Pg in 2017 is not only when the BLA is approved but also how quickly PLI can implement their marketing strategy. This involves identifying people with congenital deficiency and getting them on treatment and getting the product into hospitals. I expect that the roll-out will take time so I don't have high revenue expectations for 2017. This contrasts with IVIG which is expected to be approved in H2 2018 as all inventory of IVIG can immediately be put on the market sold easily thru distributors.